8-K: XOMA Royalty Completes Mural Oncology Acquisition

XOMA Royalty Corporation has successfully completed its acquisition of Mural Oncology plc for $2.035 per share in cash, effective December 5, 2025.

Summary

• XOMA Royalty Corporation (XOMA) has completed its previously announced acquisition of Mural Oncology plc (Mural) through an Irish High Court sanctioned scheme of arrangement.
• Mural shareholders received a cash consideration of $2.035 per share.
• Outstanding Mural options were cancelled and converted into a cash right equal to the consideration minus the exercise price; options with an exercise price equal to or greater than the consideration received no payment.
• Outstanding Mural restricted stock units (RSUs) were cancelled and converted into a cash right equal to the consideration.
• Mural's shares ceased trading on Nasdaq on December 5, 2025, and the company intends to promptly delist from Nasdaq and deregister under the Securities Exchange Act of 1934.

Sentiment

Score: 8

Explanation: The successful completion of a strategic acquisition is generally positive for the acquiring company, indicating effective execution of its growth strategy and expansion of its asset portfolio. The clear cash consideration provides certainty for the acquired company's shareholders.

Positives

• Successful completion of a strategic acquisition, expanding XOMA Royalty's portfolio of biotech royalty assets.
• Mural shareholders received a definitive cash price per share, providing liquidity and certainty.

Risks

• Forward-looking statements are subject to risks, including potential delays in the timing of the payment of the consideration and delisting of Mural's shares.
• Other potential risks are described in XOMA Royalty's most recent filings on Form 10-K and Form 10-Q.

Future Outlook

XOMA Royalty disclaims any obligation to update forward-looking statements, except as required by applicable law, regarding the payment and timing of consideration to former Mural shareholders and the ability and timing of delisting of Mural's shares.

Management Comments

• XOMA Royalty's board of directors and XRA 5 Corp.'s (Sub) board of directors accept responsibility for the information contained in this announcement.
• To the best of the knowledge and belief of XOMA Royalty's board of directors and Sub's board of directors (who have taken all reasonable care to ensure that this is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

Industry Context

XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economics from pre-commercial and commercial therapeutic candidates. This acquisition of Mural Oncology plc aligns with XOMA's strategy to expand its portfolio and provide non-dilutive funding to biotech companies, reinforcing its role in the biotech financing ecosystem.

Management Changes

Corporate Governance

Stakeholder Impact

• **Mural Shareholders**: Received a cash consideration of $2.035 per share, providing a definitive exit from their investment.
• **XOMA Royalty Shareholders**: The acquisition expands XOMA's portfolio of royalty assets, potentially enhancing future revenue streams and long-term value.
• **Mural Employees**: The filing mentions the 'Wind-Down Process' and 'Estimated Post-Closing Costs' associated with it, implying potential job impacts. However, XOMA has committed to honoring compensation, employment, severance, and change-of-control agreements.
• **Mural Management/Directors**: Existing directors are expected to resign, and new directors will be appointed by XOMA, marking a change in leadership and strategic direction for the acquired entity.

Next Steps

• Mural's shares will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934.
• XOMA Royalty will pay the aggregate consideration to former Mural shareholders.
• Financial statements of Mural and unaudited pro forma condensed combined financial information of XOMA and Mural will be filed in an amendment to this Current Report on Form 8-K.

Key Dates

Recommendation

This filing announces the completion of a previously disclosed acquisition, which is a past event. While the acquisition is a strategic move for XOMA Royalty, this specific report does not provide new financial performance data or forward-looking guidance that would immediately alter the investment thesis. Investors should continue to monitor XOMA's overall financial health and the integration of the acquired assets for future performance indicators. Therefore, a 'hold' recommendation is appropriate as it confirms a strategic action without providing immediate new performance indicators.

Keywords

XOMA Royalty, Mural Oncology, Acquisition, Biotech, Royalty Aggregator, Scheme of Arrangement, Nasdaq Delisting, SEC Filing, 8-K